ABG Sundal Collier Upgrades Mycronic AB to ‘Buy’ Amid Market-Making Moves and Analyst Focus
ABG Sundal Collier, a Norwegian capital-markets group, has upgraded its recommendation for Mycronic AB to ‘buy’ and highlighted the potential for undervalued defence stocks, demonstrating its strategic positioning in the Nordic capital-markets arena.
4 minutes to read